Skip to content

First Parkinson’s patient administered a stem cell-based transplant in clinical trial

A patient suffering from moderate Parkinson’s disease (PD) was first out on Feb 13, 2023, to receive a transplant with the human stem cell-derived nerve cell product STEM-PD at Skåne University Hospital in southern Sweden. This is the result of a decade long research effort in which reNEW Copenhagen’s Associate Professor Agnete Kirkeby led the pre-clinical development of the cell product.

The STEM-PD product is an embryonic stem cell-derived product consisting of human dopamine neuron progenitor cells for transplantation to the brains of Parkinson’s disease patients. The hope is that these stem cells will mature into new and healthy dopamine-producing nerve cells within the brains of the trial participants and thereby alleviate the patients’ parkinsonian symptoms.

The cell product used has gone through rigorous pre-clinical tests to meet the quality standards of the Swedish Medical Products Agency.

Today, around eight million people around the globe live with Parkinson’s, a debilitating disease which leads to tremors, stiffness and/or the slowing of movements. The standard treatment at hand are medications which over time often loose effectiveness and cause side effects.

CLICK HERE to read the full article